Pearl Bio
Stamford, US · Founded 2020 · Delaware corporation · 1 known investors
Pearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.
BiotechDeep TechNew Materials
Founders & leadership
Pearl Bio was founded in 2020 by Farren Isaacs, Michael Jewett, and Amy Cayne Schwartz.
FI
Farren IsaacsCo-Founder and Science Advisor
MJ
Michael JewettCo-Founder and Science Advisor
AC
Amy Cayne SchwartzinCo-Founder, COO & CBO
MG
Merton GollaherExecutive
Board
GC
George ChurchScience Advisor
JR
Jesse RinehartScience Advisor
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.1M disclosed across 1 round · 2021
▶$4.1MraisedOct 2021 · 3 investors · BiotechnologyRule 506(b)
▶$4.1MraisedOct 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Merton GollaherExecutive Officer
- Farren IsaacsExecutive Officer, Director
- Michael JewettExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $4.1M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapPillar Biosciences9 shared keywordsPillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.
Pattern5 shared keywordsPattern Bioscience develops a single-cell microbiology system with rapid identification and antimicrobial susceptibility testing (ID/AST) panels to diagnose bacterial infections and guide targeted antibiotic treatment days faster. It serves clinical laboratories and addresses antibiotic resistance in infectious disease diagnostics.
Pear Bio5 shared keywordsPear Bio delivers precision medicine tests and therapeutics for patients with hard-to-treat cancers by creating personalized treatment predictions from tumor biopsies and developing novel targeted therapies.
Parallel Bio5 shared keywordsParallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
Companies competing with Pearl Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2023 | $274.5K |
| Department of DefenseOffice of the Secretary of Defense | Phase ISTTR | 2023 | $250K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Pearl Bio do?
- Pearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.
- Who founded Pearl Bio?
- Pearl Bio was founded by Farren Isaacs, Michael Jewett, Amy Cayne Schwartz in 2020.
- Who are Pearl Bio's investors?
- Pearl Bio's investors include Khosla Ventures.
- How much funding has Pearl Bio raised?
- Pearl Bio has disclosed $4.1M raised across 1 round.
- Where is Pearl Bio headquartered?
- Pearl Bio is headquartered in Stamford, US.